OKYO Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
OKYO Pharma Ltd. furnished this Form 6-K on August 30, 2022. The filing reports a United Kingdom news service announcement regarding development of OK-101 for dry eye disease. The company files annual reports on Form 20-F.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes Versus Prior Period
The filing text does not provide comparative financial information or identify material period-over-period financial changes.
Guidance, Outlook, Risks, and Unusual Items
- OKYO Pharma announced plans to file an Investigational New Drug application for OK-101 in the fourth quarter of 2022.
- The stated indication is dry eye disease.
- The company planned to initiate a subsequent Phase 2 clinical trial, alongside peptide manufacturing partner AmbioPharm.
- The filing text does not provide specific trial milestones, financing plans, cost estimates, regulatory contingencies, or risk-factor detail.
- The underlying announcement was furnished as Exhibit 99.1 and was not deemed filed for purposes of Section 18 of the Securities Exchange Act, nor incorporated by reference except as expressly provided.
Important Facts for Investors to Verify
- Whether the planned Q4 2022 IND filing for OK-101 occurred on schedule.
- The regulatory status and design of the planned Phase 2 dry-eye-disease trial.
- OKYO Pharma’s available cash, expected development costs, and financing requirements, which are not disclosed in this filing text.
- The terms and scope of the manufacturing relationship with AmbioPharm.